Alsina, Melissa <br/><br/>
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Sep 2012 
 - 4830-40 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-11-3007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Drug-Related Side Effects and Adverse Reactions--chemically induced<br/>Female<br/>Humans<br/>Lymphoma--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Oligopeptides--administration & dosage<br/>Proteasome Inhibitors--administration & dosage<br/>Recurrence